Post copied from Attitudes of incoming US politicians to ME/CFS and post-Covid 19 illness Details below. Basically, they aim to recruit a lot of people with a positive diagnosis for SARS-COV2 and follow them for 18 months, with ME/CFS as the primary outcome. (I think that's quite a strong connection with ME/CFS.) Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE) Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE) Sponsors Lead Sponsor: Rush University Medical Center Collaborator: Yale University University of Washington Thomas Jefferson University University of California, Los Angeles University of California, San Francisco University of Texas Southwestern Medical Center The University of Texas Health Science Center, Houston Source Rush University Medical Center Brief Summary This study will use a digital platform to longitudinally track comprehensive information including patient self-report as well as data that describe the process and outcome of care in the electronic medical record (EMR) of a large representative sample of patients under investigation for SARSCOV2. The objective is to generate knowledge rapidly using digital tools and collaborative sciences to produce real-time data, analysis, and reporting compared to more traditional approaches. An additional goal is to promote an open science approach whereby scientists, with proper approvals and in line with the permissions granted by the participants, have the opportunity to work with data in ways that protects individual privacy but promotes rapid dissemination and implementation of knowledge. Overall Status Not yet recruiting Start Date November 14, 2020 Completion Date November 14, 2022 Primary Completion Date November 14, 2022 Study Type Observational [Patient Registry] >> Primary Outcome Incident myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) 18 months post enrollment<< Secondary Outcome Measure Time Frame Ambulatory care and/or ED visits post enrollment 18 months post enrollment Hospitalizations post enrollment 18 months post enrollment Death during hospital admission 18 months post enrollment Hospital-free survival 18 months post enrollment ICU-free survival 18 months post enrollment Enrollment 4800 Condition Covid19 ME/CFS SARS COV2 Novel Coronavirus Infection Neurocognitive Disorders Cardiovascular Diseases Eligibility Sampling Method: Non-Probability Sample Criteria: INCLUSION CRITERIA 1. Fluent in English or Spanish; 2. Age 18 and over; 3. Self-reported symptoms suggestive of acute SARSCOV2 infection; 4. Under investigation for SARSCOV2 (defined as a patient who has received any screening or diagnostic test used to detect the presence of COVID19 including any FDA approved or authorized molecular or antigen-based assay) within the last 28 days. EXCLUSION CRITERIA 1. Unable to provide informed consent; 2. Study team unable to confirm result of diagnostic test for SARSCOV2; 3. Does not have access to a hand-held device or computer that would allow for digital participation in the study; 4. Individuals who are prisoners while participating in the study.